Novo Nordisk plans to ramp up current investments and allocate USD 6.8 billion to production in 2024, a significant increase from investments of USD 3.9 billion* in the previous year.
Bagsvaerd, Denmark, June 24, 2024 Novo Nordisk today announced plans to invest US$4.1 billion (approximately DKK 27 billion) to build a second fill-finish manufacturing facility in Clayton, North Carolina, to increase production capacity for current and future injectable therapies for people living with obesity and other serious chronic diseases.
The expansion, the largest manufacturing investment in Novo Nordisk’s history, will add 1.4 million square feet of production space for sterile and finished product manufacturing processes, doubling the combined size of the company’s three existing facilities in North Carolina. It will also create 1,000 new jobs to join the approximately 2,500 Novo Nordisk employees already working in the region, which is at the heart of U.S. innovation and biotechnology.
“It took a century to reach 40 million patients, but with this expansion and our continued investment in global production, Novo Nordisk is building the capacity to serve millions more people with serious chronic diseases in the future,” said Lars Fluagaard Jorgensen, president and CEO of Novo Nordisk. “This is another sure sign of our efforts to scale up production to meet the growing global demand for our life-changing medicines and the patients of the future.”
Utilizing cutting-edge technology, rooftop solar panels and innovative water strategies, the facility is designed in an efficient and environmentally sustainable manner to provide the highest quality products to patients around the world. The goal is to achieve LEED Gold certification, the recognized standard of excellence in the construction of healthy, efficient, carbon- and cost-saving green buildings.
“Clayton is Novo Nordisk’s first manufacturing site in the United States, and this new major investment underscores the continued importance of our manufacturing facility there as a cornerstone of our growth,” said Henrik Wolf, executive vice president, Product Supply, Quality and IT, Novo Nordisk. “For decades, we have partnered with North Carolina to develop a well-trained, committed and diverse local workforce. In Clayton and at our manufacturing sites around the world, we are driven by one purpose: to deliver more for the millions of people living with chronic conditions, and this facility will help us achieve just that.”
Initial grading and foundation work is already underway in preparation for the 56-acre facility site. Construction is expected to be completed incrementally between 2027 and 2029. At the project’s peak, approximately 2,000 outside contractors are expected to be involved.
“This is a historic day for Johnston County,” said Johnston County Commission Chairman Butch Lauther, who announced the county grant to further support the expansion project at a press conference today. “Thirty-one years ago, Novo Nordisk decided to locate a new home here in Clayton, and in 2016 announced they would build a new facility directly across the street, which at the time was the largest life sciences investment in state history. Today, Novo Nordisk is on track to break that record again with their third facility, 1,000 new jobs, and a show of confidence in the partnerships they’ve built in the community over decades.”
Novo Nordisk plans to invest about US$6.8 billion (DKK 45 billion) in production in 2024 to increase actual investments and boost supply, compared with actual investments of US$3.9 billion (DKK 26 billion) last year.
For photos and b-roll supporting this press release, please visit novonordisk.com.
About Novo Nordisk Manufacturing
Novo Nordisk operates in Denmark, the United States, France,
All Novo Nordisk’s medicines are manufactured at these sites and then delivered to patients around the world, including nearly half of the world’s insulin, GLP-1 medicines for the treatment of diabetes and obesity, and medicines for rare diseases such as hemophilia and growth disorders. Novo Nordisk’s manufacturing division employs around 20,000 people who are committed to delivering the highest quality medicines to patients around the world in an efficient and environmentally sustainable way.
About Novo Nordisk
Founded in 1923, Novo Nordisk is a leading global healthcare company headquartered in Denmark. Building on our heritage in diabetes, our purpose is to drive transformation to overcome serious chronic diseases. We are pioneering scientific breakthroughs, expanding access to medicines and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 66,000 people in 80 countries and markets products in approximately 170 countries. For more information, please visit www.novonordisk.com/. Novo Nordisk, Facebook, Instagram, X, LinkedIn and Youtube.
Contact for more information
*Acquisitions not included
Attachments
